In a report released on March 6, Marc Goodman from SVB Securities maintained a Buy rating on Eliem Therapeutics (ELYM – Research Report), with a price target of $4.00. The company’s shares closed yesterday at $3.64.
According to TipRanks, Goodman is a 3-star analyst with an average return of 2.3% and a 46.15% success rate. Goodman covers the Healthcare sector, focusing on stocks such as Denali Therapeutics, Evolus, and ACADIA Pharmaceuticals.
The word on The Street in general, suggests a Hold analyst consensus rating for Eliem Therapeutics with a $6.00 average price target.
See Insiders’ Hot Stocks on TipRanks >>
ELYM market cap is currently $92.99M and has a P/E ratio of -2.05.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Eliem Therapeutics Inc is a clinical-stage biotechnology company. It is focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems.
Read More on ELYM:
- Eliem Therapeutics Reports Fourth Quarter and Year-End Financial Results and Business Highlights
- Eliem Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
- Eliem :CEO Azelby, COO & CFO Lavelle, and Jim Bucher, general counsel, to depart
- Eliem to re-prioritize pipeline, reduce workforce by 55% in 1H23
- Eliem to re-prioritize pipeline, pausing ETX-155 development for MDD
